Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 441

Results For "LA"

8065 News Found

Cureskin secures US$ 20 million in Series B funding
News | March 14, 2024

Cureskin secures US$ 20 million in Series B funding

Cureskin aims to disrupt the large and growing skin and hair care industry in India


Zydus receives USFDA final approval for chlorpromazine hydrochloride injection
Drug Approval | March 14, 2024

Zydus receives USFDA final approval for chlorpromazine hydrochloride injection

Chlorpromazine Hydrochloride Injection is used to treat certain mental/mood disorders


Evonik establishes a new research institute dedicated to skin sciences
News | March 13, 2024

Evonik establishes a new research institute dedicated to skin sciences

New institute brings together Evonik’s most advanced biotech platform and a global network of evaluation labs


European Commission approves Pfizer’s Prevenar 20 to help protect infants and children against pneumococcal disease
Drug Approval | March 13, 2024

European Commission approves Pfizer’s Prevenar 20 to help protect infants and children against pneumococcal disease

PREVENAR offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine to help protect infants and children from the 20 serotypes responsible for the majority of currently circulating pneumococcal disease in the EU and globally


Nirma acquires majority stake in Glenmark Life Sciences
News | March 13, 2024

Nirma acquires majority stake in Glenmark Life Sciences

Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals


Healthcare Triangle appoints Anand Kumar as Interim CEO
People | March 13, 2024

Healthcare Triangle appoints Anand Kumar as Interim CEO

Anand is committed to leading the company's continued commitment to driving innovation in Health Care through the utilization of Digital transformation, AI and LLM


Pfizer announces positive Phase 3 trial of ADCETRIS regimen in patients with DLBCL
Clinical Trials | March 12, 2024

Pfizer announces positive Phase 3 trial of ADCETRIS regimen in patients with DLBCL

Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS


Merck completes acquisition of Harpoon Therapeutics
News | March 12, 2024

Merck completes acquisition of Harpoon Therapeutics

Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager